Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
PMV Pharmaceuticals is a precision oncology company focused on developing small molecule therapies targeting p53 mutations, a common driver in over half of all cancers. Its lead candidate, rezatapopt, aims to structurally correct specific p53 mutations, such as Y220C, across multiple tumor types. The company advances tumor-agnostic, gene-specific treatments through clinical trials, leveraging genomic sequencing and targeted drug development to improve cancer patient outcomes.
This description was generated via AI from an annual report. Updated about 1 year ago.